SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMCNet:  Research and Markets: Investigation Report on China's Insulin Lispro Market, 2009-2018

[March 19, 2014]

Research and Markets: Investigation Report on China's Insulin Lispro Market, 2009-2018

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/t4hv68/investigation) has announced the addition of the "Investigation Report on China's Insulin Lispro Market, 2009-2018" report to their offering.

According to IDF (the International Diabetes Federation), incidence of diabetes among adults aged 20-79 in the world was 8.3% in 2013 with 382 million patients worldwide. The number of diabetes patients in China was more than 98 million, ranking the first in the world. The rapid growth of diabetes patients is becoming a serious economic and social issue in China and other developing countries.

The first ultra-short-acting human insulin analogue insulin lispro (produced by Eli Lilly and Company with the trade name ""Humalog"") was launchedin 1996 and approved by FDA. Insulin lispro is a fast acting insulin analogue with one primary advantage over regular insulin for postprandial glucose control. It has a shortened delay of onset, allowing slightly more flexibility than regular insulin, which requires a longer waiting period before starting a meal after injection. In 2012, global sales revenue of Humalog reached nearly USD 2.4 billion.


Humalog was launched in China in 2005 and its annual sales revenue continues to grow rapidly. According to CRI's (News - Alert) investigation on certain Chinese sample hospital market, the sales revenue of insulin lispro in Chinese hospitals grew more than 100 times from 2005 to 2013. Most of the market is occupied by Eli Lilly and Company while the other belongs to Gan & Lee Pharmaceuticals. There used to be legal disputes between the two companies over the patent of insulin lispro in China. Based on CRI's investigation, insulin lispro produced by other Chinese enterprises will soon appear on the market.

Key Topics Covered:

1 Relevant Concepts of Insulin Lispro

2 Market Overview of Insulin Lispro in China

3 Investigation on Sales Value of Insulin Lispro in China, 2009-2013

4 Investigation on Market Share of Major Insulin Lispro Manufacturers in China, 2009-2013

5 Investigation on Market Size of Insulin Lispro by Dosage Form in China, 2009-2013

6 Reference Price of Insulin Lispro Produced by Different Enterprises in China Hospital Market, 2014

7 Major Manufacturing Enterprises in China Insulin Lispro Market, 2009-2013

8 Prospect of China Insulin Lispro Market, 2014-2018

For more information visit http://www.researchandmarkets.com/research/t4hv68/investigation


[ Back To Technology News's Homepage ]

OTHER NEWS PROVIDERS







Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved.